Spots Global Cancer Trial Database for teclistamab
Every month we try and update this database with for teclistamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | NCT05243797 | Multiple Myelom... | Teclistamab Lenalidomide | 18 Years - | Stichting European Myeloma Network | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | NCT05463939 | Relapsed or Ref... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05572515 | Relapsed or Ref... | Teclistamab Pomalidomide Bortezomib Dexamethasone Carfilzomib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | NCT05243797 | Multiple Myelom... | Teclistamab Lenalidomide | 18 Years - | Stichting European Myeloma Network | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | NCT06208150 | Relapsed or Ref... | Talquetamab Pomalidomide Teclistamab Elotuzumab Dexamethasone Bortezomib | 18 Years - | Janssen Research & Development, LLC | |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | NCT05469893 | High-risk Smold... Smoldering Mult... Multiple Myelom... | Teclistamab Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04586426 | Multiple Myelom... | Talquetamab Teclistamab Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05572515 | Relapsed or Ref... | Teclistamab Pomalidomide Bortezomib Dexamethasone Carfilzomib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04557098 | Hematological M... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma | NCT06359067 | Multiple Myelom... | Treated by bisp... Not treated by ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma | NCT06359067 | Multiple Myelom... | Treated by bisp... Not treated by ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | NCT04696809 | Hematologic Mal... | Teclistamab | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | NCT05552222 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide Dexamethasone Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT04586426 | Multiple Myelom... | Talquetamab Teclistamab Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| Horizon Adaptive Platform Trial Evaluating Therapies in RRMM | NCT06171685 | Relapse Multipl... Refractory Mult... | Teclistamab Investigational... | 18 Years - 99 Years | Multiple Myeloma Research Consortium | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | NCT05552222 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide Dexamethasone Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05083169 | Multiple Myelom... | Daratumumab Pomalidomide Dexamethasone Bortezomib Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | NCT05463939 | Relapsed or Ref... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | NCT05572229 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide | 65 Years - | University Hospital, Lille | |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | NCT06353022 | Multiple Myelom... | Teclistamab Talquetamab Lenalidomide Bortezomib Daratumumab Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | NCT05552222 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide Dexamethasone Talquetamab | 18 Years - | Janssen Research & Development, LLC | |
| Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) | NCT06100237 | Multiple Myelom... | Teclistamab Talquetamab Daratumumab SC | 18 Years - | University of Miami | |
| Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | NCT05849610 | High-Risk de No... | Daratumumab Bortezomib Lenalidomide Teclistamab Talquetamab | 18 Years - | PETHEMA Foundation | |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | NCT05572229 | Multiple Myelom... | Teclistamab Daratumumab Lenalidomide | 65 Years - | University Hospital, Lille | |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | NCT06353022 | Multiple Myelom... | Teclistamab Talquetamab Lenalidomide Bortezomib Daratumumab Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| Plan Development for Giving Teclistamab in the Outpatient Setting | NCT06251076 | Multiple Myelom... Relapsed Cancer Refractory Canc... | Teclistamab Tocilizumab | 18 Years - | University Health Network, Toronto | |
| Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) | NCT05161598 | Multiple Myelom... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | NCT06425991 | Relapsed or Ref... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | NCT05463939 | Relapsed or Ref... | Teclistamab | 18 Years - | Janssen Research & Development, LLC | |
| Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients | NCT06062537 | Multiple Myelom... | 18 Years - | Intergroupe Francophone du Myelome |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
